Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Preliminary Safety and Efficacy of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia: Selclax

Sara Zarnegar-Lumley, Seth E. Karol, Stanley Pounds, Jeffery M. Klco, Maria Luisa Sulis, Dennis John Kuo, Kenneth Matthew Heym, Kathleen Ludwig, Alexandra McLean Stevens, Thomas B. Alexander, Kelly Elizabeth Faulk, Himalee S. Sabnis, Sarah K. Tasian, Jeffrey Taub, Andrew E. Place, Jeffrey E. Rubnitz

Blood (2023) 142 (Supplement 1): 56.

https://doi.org/10.1182/blood-2023-174342

Published: 2023

Journal Articles

Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes

Jatinder K. Lamba, Richard J Marrero, Huiyun Wu, Xueyuan Cao, Phani Krishna Parcha, Seth E. Karol, Hiroto Inaba, Dennis John Kuo, Barbara Degar, Kenneth Matthew Heym, Jeffrey Taub, Norman J. Lacayo, Ching-Hon Pui, Raul C. Ribeiro, Stanley Pounds, Jeffrey E. Rubnitz

Blood (2023) 142 (Supplement 1): 386.

https://doi.org/10.1182/blood-2023-173617

Published: 2023

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

At Clinically Achievable Concentrations Obatoclax (GX15-070) Potentiates The Cytotoxic Effect Of Cytarabine On Acute Myeloid Leukemia Cells By Enhancing DNA Damage

Yubin Ge, PhD, Chengzhi Xie, Holly Edwards, J. Timothy Caldwell, Jeffrey Taub, MD

Blood (2013) 122 (21): 3829.

https://doi.org/10.1182/blood.V122.21.3829.3829

Published: 2013

Journal Articles

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

Alan S. Gamis, Todd A. Alonzo, Robert B. Gerbing, Joanne M. Hilden, April D. Sorrell, Mukta Sharma, Thomas W. Loew, Robert J. Arceci, Dorothy Barnard, John Doyle, Gita Massey, John Perentesis, Yaddanapudi Ravindranath, Jeffrey Taub, Franklin O. Smith

Blood (2011) 118 (26): 6752–6759.

https://doi.org/10.1182/blood-2011-04-350017

Published: 2011

Includes: Supplemental data

Journal Articles

Inhibition of Histone Deacetylases 1 and 6 Enhances Ara-C-Induced Apoptosis In Pediatric Acute Myeloid Leukemia Cells

Xuelian Xu, Chengzhi Xie, Holly Edwards, Hui Zhou, Steven Buck, Larry Matherly, PhD, Jeffrey Taub, MD, Yubin Ge, PhD

Blood (2010) 116 (21): 3275.

https://doi.org/10.1182/blood.V116.21.3275.3275

Published: 2010

Journal Articles

Overexpression of GATA1 Confers Chemotherapy Resistance in Pediatric Acute Megakaryocytic Leukemia.

Holly Edwards, Chengzhi Xie, Alan Dombkowski, Maggie Keller, Mark Stout, Steven Buck, Larry Matherly, PhD, Jeffrey Taub, MD, Yubin Ge, PhD

Blood (2009) 114 (22): 2039.

https://doi.org/10.1182/blood.V114.22.2039.2039

Published: 2009

Journal Articles

Synergistic Antileukemic Interactions Between Valproic Acid and Cytarabine: A Potential Means to Improve the Treatment of Pediatric Acute Myeloid Leukemia.

Chengzhi Xie, Holly Edwards, Lisa Polin, Hui Zhou, Xuanlin Wang, Song Yang, Salvatore B LoGrasso, Steven Buck, Mark Stout, Jeffrey Rubnitz, MD, PhD, Larry Matherly, PhD, Jeffrey Taub, MD, Qun Yu, Yubin Ge, PhD

Blood (2009) 114 (22): 2084.

https://doi.org/10.1182/blood.V114.22.2084.2084

Published: 2009

Journal Articles

Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome.

Maureen O'Brien, MD, Gary Dahl, MD, Stanley Pounds, Norman J. Lacayo, MD, Jeffrey Taub, MD, Myron Chang, Howard J. Weinstein, MD, Yaddanapudi Ravindranath, MBBS, Dario Campana, MD, PhD, Ching-Hon Pui, MD, Jeffrey Rubnitz, MD, PhD

Blood (2009) 114 (22): 482.

https://doi.org/10.1182/blood.V114.22.482.482

Published: 2009

Journal Articles

Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.

Jeffrey Rubnitz, MD, PhD, Hiroto Inaba, MD, PhD, Gary Dahl, MD, W. Paul Bowman, Jeffrey Taub, MD, Ching-Hon Pui, MD, Stanley Pounds, Norman J. Lacayo, MD, Xueyuan Cao, Raul C. Ribeiro, MD, Soheil Meshinchi, MD, PhD, Barbara Degar, MD, Gladstone Airewele, Mihaela Onciu, MD, Elaine Coustan-Smith, MS, Dario Campana, MD, PhD

Blood (2009) 114 (22): 16.

https://doi.org/10.1182/blood.V114.22.16.16

Published: 2009

Journal Articles

Excessive Cardiotoxicity Despite Excellent Leukemia-Free Survival for Pediatric Patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML): Results from POG (Pediatric Oncology Group) Protocol 9421.

Maureen O’Brien, MD, Jeffrey Taub, MD, Kimo Stine, MD, Myron Chang, Yaddanapudi Ravindranath, MD, David Becton, MD, Gary Van Houten Dahl, MD

Blood (2006) 108 (11): 559.

https://doi.org/10.1182/blood.V108.11.559.559

Published: 2006

Journal Articles

Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial.

Jeffrey Rubnitz, MD, PhD, Bassem Razzouk, MD, Paul Bowman, MD, Gary Dahl, MD, Norman Lacayo, MD, Jeffrey Taub, MD, Yaddanapudi Ravindranath, MD, Soheil Meshinchi, MD, PhD, Gladstone Airewele, MD, Shelly Lensing, MS, Stanley Pounds, PhD, Raul Ribeiro, MD, Ching-Hon Pui, MD, Elaine Coustan-Smith, MS, Dario Campana, MD

Blood (2005) 106 (11): 275.

https://doi.org/10.1182/blood.V106.11.275.275

Published: 2005

NARROW

Preliminary Safety and Efficacy of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia: Selclax

Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

At Clinically Achievable Concentrations Obatoclax (GX15-070) Potentiates The Cytotoxic Effect Of Cytarabine On Acute Myeloid Leukemia Cells By Enhancing DNA Damage

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

Inhibition of Histone Deacetylases 1 and 6 Enhances Ara-C-Induced Apoptosis In Pediatric Acute Myeloid Leukemia Cells

Overexpression of GATA1 Confers Chemotherapy Resistance in Pediatric Acute Megakaryocytic Leukemia.

Synergistic Antileukemic Interactions Between Valproic Acid and Cytarabine: A Potential Means to Improve the Treatment of Pediatric Acute Myeloid Leukemia.

Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome.

Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.

Excessive Cardiotoxicity Despite Excellent Leukemia-Free Survival for Pediatric Patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML): Results from POG (Pediatric Oncology Group) Protocol 9421.

Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only